Top

Published in:

01-02-2011 | Gynecologic Oncology

Dydrogesterone and other progestins in benign breast disease: an overview

Author: Adolf E. Schindler

Published in: Archives of Gynecology and Obstetrics | Issue 2/2011

Abstract

Progestogens appear to have a dual effect on the cell cycle in breast cells and breast cancer cells. There is initially stimulation of mitotic activity. However, continuous application leads to cell apoptosis. This depends on type, dose and length of progestogen application in relation to estrogen action. In benign breast disease the use of progestogens results not only in reduction of mastodynia, but also a reduction in breast gland size and disappearance of nodularity proven by clinical examination and follow-up including breast ultrasound.

Schindler AE (1989) Ätiologie und Epidemiologie gutartiger Veränderungen der Brust. Gynäkologe 22:212–215PubMed

Eden J (2003) Progestins and breast cancer. Am J Obstet Gynecol 188:1123–1131CrossRefPubMed

Sitruk-Ware R, Mishell DR (2000) Progestins and antiprogestins in clinical practice. Marcel Dekker, New York

Musgrove EA, Lee CSL, Sutherland R (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression, while increasing expression of transforming growth factor, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 11:5032–5043PubMed

Plu-Bureau G, Le M, Sitruk-Ware R, Thalabard J (1994) Progestogen use and the decreased risk of breast cancer in a cohort of premenopausal women with benign breast disease. Br J Cancer 70:270–277CrossRefPubMed

Mauvais-Javis P (1988) Mastodynia and fibrocystic breast disease. Curr Ther Endocrinol Metab 3:280–284

Barrat J, de Lignieres B, Marpeau L et al (1990) Effect in vivo de l′adminstration locale de progesterone sur l′activité mitotique de galactophores humaines. J Gyn Obstet Biol Reprod 19:269–274

Chang KJ, Lee TTY, Linares-Gruz G (1995) Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fert Steril 63:785–791

Kutten F, Malet C, Leygue E et al (1994) Antiestrogen action of progestogens in human breast cells. In: Berg G, Hammar M (eds) The modern management of menopause. Canforth, Parthenon, pp 419–433

10.

Rohan TE, Negassa A, Chlebowski RT et al (2008) Estrogen plus progestogen and risk of benign proliferative breast disease. Cancer Epidemiol Biomark Prev 17:2337–2343CrossRef

11.

Seeger H, Wallwiener D, Mueck AO (2003) The effect of progesterone and synthetic progestins in serum and estradiol-stimulated proliferation of human breast cancer cells. Hormone Metab Res 55:76CrossRef

12.

Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C (2001) Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol Endocrinol 15(Suppl 6):37–43PubMed

13.

Goebel R, Junkermann R, von Fournier D (1989) Danazol-Therapie bei gutartigen Brusterkrankungen. Gynäkologe 22:262–270

14.

Uzan S, Denis C, Pomi V, Varin C (1992) Double-blind trial of promegestone (R5020) and lynestrenol in the treatment of benign breast disease. Eur J Gynecol Obstet Reprod Biol 43:219–227CrossRef

15.

Vorher H (1988) Gutartige Brustveränderungen: Was ist in Praxi zu tun? Gyne International 6:5–10

16.

Schindler AE, Henkel A, Christensen B, Moore C, Oettel M (2009) Dienogest and the breast. Gynecol Endocrinol 25:472–474CrossRefPubMed

17.

V Fournier D, Kubli F, Bauer M, Weber E (1981) Hochdosierte Gestagen-Langzeit-Therapie beim Corpuskarzinom, Einfluss auf Überlebenszeit. Geburtsh Frauenheilk. 41:266–270

Title: Dydrogesterone and other progestins in benign breast disease: an overview
Author: Adolf E. Schindler
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 2/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-010-1456-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dydrogesterone and other progestins in benign breast disease: an overview

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Serous borderline tumor of the fallopian tube presented as an adnexal mass

Is single umbilical artery an independent risk factor for perinatal mortality?

Ethnic differences in age-related changes of postpartum hemoglobin levels

Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV− mothers: a meta-analysis

Calprotectin, RAGE and TNF-α in hypertensive disorders in pregnancy: expression and significance

Genetic variation in the CYP17 gene and recurrent spontaneous abortions